z-logo
Premium
Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria
Author(s) -
Konrad Katja,
Datz Nicolin,
Engelsberger Ilse,
GrulichHenn Jürgen,
Hoertenhuber Thomas,
Knauth Burkhild,
Meissner Thomas,
Wiegand Susanna,
Woelfle Joachim,
Holl Reinhard W.
Publication year - 2015
Publication title -
pediatric diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.678
H-Index - 75
eISSN - 1399-5448
pISSN - 1399-543X
DOI - 10.1111/pedi.12203
Subject(s) - medicine , metformin , diabetes mellitus , type 2 diabetes mellitus , insulin , type 1 diabetes , intensive care medicine , pediatrics , endocrinology
Background With increasing obesity in childhood and adolescence, weight gain, and insulin resistance become also more frequent in patients with type 1 diabetes mellitus (T1DM). Especially during puberty, insulin therapy often has to be intensified and higher insulin doses are necessary. Some studies point to a beneficial effect of metformin in addition to insulin in these patients. In order to describe current practice and possible benefits, we compared pediatric T1DM patients with insulin plus metformin (n = 525) to patients with insulin therapy only (n = 57 487) in a prospective multicenter analysis. Methods Auxological and treatment data from 58 012 patients aged <21 yr with T1DM in the German/Austrian Diabetes Patienten Verlaufsdokumentation (DPV) registry were analyzed by multivariable mixed regression modeling. Results Patients with additional metformin were older [median (interquartile range)]: [16.1 (14.1–17.6) vs. 15.2 (11.5–17.5) yr] with female preponderance (61.0 vs. 47.2%, p < 0.01). They had higher body mass index‐standard deviation score (BMI‐SDS) [+2.03 (+1.29 to +2.56) vs. +0.51 (−0.12 to +1.15); p < 0.01] and glycated hemoglobin (HbA1c) (9.0 vs. 8.6%, p < 0.01). Hypertension (43.7 vs. 24.8%) and dyslipidemia (58.4 vs. 40.6%) were significantly more prevalent. Adjusted insulin dose was significantly higher (0.98 vs. 0.93 IU/kg bodyweight). In a subgroup of 285 patients followed‐up longitudinally (average treatment period 1.42 yr), addition of metformin resulted in a slight reduction of BMI‐SDS [−0.01 (−2.01 to +1.40)], but did not improve HbA1c or insulin requirement. Conclusion Additional metformin therapy in T1DM is primarily used in obese females. Additional therapy with metformin was associated with minor benefits.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here